Secondary Prevention of Clostridioides Difficile Using Vancomycin (NCT06979609)
Secondary Prophylaxis of Recurrent Clostridioides Difficile Infections During Systemic Antibiotics With Vancomycin: A Randomized Controlled Trial
🩺 Plain-English Summary (8th-Grade Level)
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode. Oral vancomycin to prevent a recurrence during antibiotic re-exposure may reduce this risk but the data supporting this practice are limited. The aim of this trial is: 1\) Does oral vancomycin prophylaxis prevent CDI recurrences in patients with recent CDI (within 120 days) and who are re-exposed to systemic antibiotics? The trial will compare oral vancomycin to placebo. Participants will: * Take the study drug (either vancomycin or placebo) twice daily for the duration of systemic antibiotics plus once daily for 7 days after completion of systemic antibiotics. * Attend an in-person or over the phone follow-up at day 56 * Respond to weekly electronic questionnaires
Who can join: Review the eligibility criteria below.
Location: McGill University Health Centre — Montreal, Quebec
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- McGill University Health Centre — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (514) 934-1934
Email: cdi@idtrials.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Clostridioides Difficile Infection
- LMN-201 for Prevention of C. Difficile Infection Recurrence — Escondido, California
- Evaluation of GeoHAI Implementation — Columbus, Ohio
- Prevention of Recurrence of Clostridioides Difficile Colitis With Ursodeoxycholic Acid (UCDA) as a Supplement to Standard Therapy — Milwaukee, Wisconsin
- Lifestyle and Recurrent Clostridioides Difficile Infection (CDI) — Ann Arbor, Michigan
- Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT) — Charlottesville, Virginia
Explore by condition: All Clostridioides Difficile Infection clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.